Xiamen Kingdomway Group Bundle
Who Owns Xiamen Kingdomway Group Company?
Understanding the ownership structure of Xiamen Kingdomway Group Company is crucial for discerning its strategic direction and governance. A pivotal moment for the company was its listing on the Shenzhen Stock Exchange on October 28, 2011, marking a significant shift in its ownership.
Founded in November 1997, Xiamen Kingdomway Group specializes in nutritional and pharmaceutical raw materials, including products like Coenzyme Q10. As of August 1, 2025, its market capitalization stood at $1.68 billion.
Who owns Xiamen Kingdomway Group Company?
Who Founded Xiamen Kingdomway Group?
Xiamen Kingdomway Group Company was established on November 24, 1997, initially under the name Xiamen Jindawei Vitamin Co., Ltd. While precise details on the initial equity distribution among its founders are not publicly disclosed, the company's early recognition as a 'key high-tech enterprise' and an 'innovative pilot enterprise of the National Torch Program' indicates a strong foundational backing. The founding vision was to be a leader in the comprehensive nutrition and health industry chain, starting with pharmaceutical raw materials.
Founding Date
Xiamen Kingdomway Group Company commenced operations on November 24, 1997. This marked the beginning of its journey in the health and nutrition sector.
Original Name
The company was originally incorporated as Xiamen Jindawei Vitamin Co., Ltd. This name reflects its initial focus on vitamin production.
Early Enterprise Status
From its inception, the company was recognized as a 'key high-tech enterprise.' It also held the designation of an 'innovative pilot enterprise of the National Torch Program,' highlighting early government support and strategic importance.
Founding Vision
The founders aimed to establish a 'pioneer in the comprehensive nutrition and health industry chain.' The initial operational focus was on manufacturing pharmaceutical raw materials.
Information Gaps
Details regarding the specific names of all founders, their initial equity percentages, or early investment rounds are not readily available. Information on early agreements or ownership disputes is also not detailed.
Initial Focus
The company's early operations were centered on the production of pharmaceutical raw materials. This laid the groundwork for its expansion into broader health and nutrition sectors.
The foundational period of Xiamen Kingdomway Group Company, established in 1997, was characterized by a clear ambition to lead within the nutrition and health industry. While the specifics of the initial ownership structure, including the exact shareholding percentages of each founder, are not publicly documented, the company's early designation as a 'key high-tech enterprise' and an 'innovative pilot enterprise of the National Torch Program' suggests a strategic alignment with national development goals and potential early-stage government or institutional support. The company's initial focus on pharmaceutical raw materials, as part of its vision to build a comprehensive nutrition and health industry chain, set the stage for its future growth and diversification. Understanding these early stages is crucial for grasping the Mission, Vision & Core Values of Xiamen Kingdomway Group and its subsequent development.
Xiamen Kingdomway Group SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Xiamen Kingdomway Group’s Ownership Changed Over Time?
Xiamen Kingdomway Group Company became a publicly traded entity on October 28, 2011, with its listing on the Shenzhen Stock Exchange under the stock symbol 002626. This transition marked a significant shift in its ownership structure, moving from private hands to a broader public investor base.
| Date | Event | Stock Symbol |
|---|---|---|
| October 28, 2011 | Public Listing on Shenzhen Stock Exchange | 002626 |
| August 1, 2025 | Shares Outstanding | 610 million |
As of August 1, 2025, Xiamen Kingdomway Group Company has 610 million shares outstanding, indicating a broad distribution of ownership. The company's ownership is now characterized by a significant presence of institutional investors, reflecting its status as a publicly traded entity. While precise holdings fluctuate, key asset management firms identified as major stakeholders include China Animal Husbandry Industry Co., Ltd., China Southern Asset Management Co., Ltd., China Asset Management Co., Ltd., Tian Hong Asset Management Co., Ltd., Shanghai Guotai Junan Securities Assets Management Co., Ltd., Fullgoal Fund Management Co., Ltd., Manulife TEDA Fund Management Co., Ltd., CCB Principal Asset Management Co., Ltd., China Merchants Fund Management Co., Ltd., and HSBC Jintrust Fund Management Co. Ltd. For historical context, Bosera Asset Management Co., Ltd. held 2.29% of shares outstanding as of June 30, 2017, and Beixin Ruifeng Fund Management Co. Ltd. held 1.41% as of October 17, 2017. These institutional holdings are crucial for understanding the Xiamen Kingdomway Group ownership landscape.
Strategic Acquisitions and Growth
The company's public listing has facilitated strategic growth through mergers and acquisitions, expanding its presence in the health industry. These investments have broadened its value chain from research and development to market distribution.
- Acquired 51% stake in Doctor's Best Holdings, Inc. for $35 million in 2015.
- Acquired 30% stake in Labrada Bodybuilding Nutrition Inc. for $8.1 million in 2017.
- Planned acquisition of a US-based nutritional supplements company for $17.2 million in 2024.
- As of March 31, 2025, total assets were $928.575 million.
- The company's strategic moves can be further understood by examining the Competitors Landscape of Xiamen Kingdomway Group.
Xiamen Kingdomway Group PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Xiamen Kingdomway Group’s Board?
The board of directors for Xiamen Kingdomway Group Company is comprised of both executive and independent members, overseeing the company's strategic direction. Bin Jiang holds the position of Chairman, alongside roles as Director, General Manager, and member of the Nomination and Strategy Committees.
| Director Name | Position(s) | Committee Membership |
|---|---|---|
| Bin Jiang | Chairman, Director, General Manager | Nomination Committee, Strategy Committee |
| Weihua Gu | Vice Chairman, Director | |
| Xiaote Xu | Director | Audit Committee |
| Hang Hong | Director, Deputy General Manager, Chief Financial Officer, Acting Secretary to the Board | |
| Jialiang Chen | Director, Executive Deputy General Manager | |
| Geng Zong | Independent Director | Audit Committee, Chairman of Nomination Committee |
| Dahong Wang | Independent Director | Chairman of Remuneration and Assessment Committee, Strategy Committee Member |
Voting power within Xiamen Kingdomway Group Company generally adheres to the one-share-one-vote principle, common for companies listed on the Shenzhen Stock Exchange. While specific details regarding dual-class shares or other control-enhancing mechanisms are not publicly detailed, the controlling shareholder, Xiamen Kingdomway Investment, held a significant portion of its stake through pledged shares. As of June 2025, these pledged shares represented 87,890,000 units, equating to 41.51% of Xiamen Kingdomway Investment's holdings and 14.41% of the company's total issued share capital. This concentration of ownership by the primary shareholder suggests a substantial influence over voting outcomes, impacting the overall Xiamen Kingdomway Group ownership structure.
Understanding Shareholder Influence
The concentration of voting power is a key factor in understanding who owns Xiamen Kingdomway Group. The controlling shareholder's significant stake, even with pledged shares, indicates a strong influence on corporate decisions.
- Xiamen Kingdomway Investment is the controlling shareholder.
- Pledged shares held by the controlling shareholder were 14.41% of total share capital as of June 2025.
- The one-share-one-vote principle typically governs voting power.
- Understanding the Growth Strategy of Xiamen Kingdomway Group requires awareness of its ownership dynamics.
Xiamen Kingdomway Group Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Xiamen Kingdomway Group’s Ownership Landscape?
Recent developments at Xiamen Kingdomway Group Company indicate a dynamic ownership landscape, with significant share pledge and release activities by its controlling shareholder, Xiamen Kingdomway Investment, in June 2025. These movements, alongside strong financial performance and strategic expansion plans, are shaping the company's trajectory and investor profile.
| Shareholder | Shareholding Percentage | Pledged Shares Percentage |
|---|---|---|
| Xiamen Kingdomway Investment | 14.41% of total share capital (as of June 2025) | 41.51% of its holdings (as of June 2025) |
The company has demonstrated robust financial growth, with operating revenues reaching RMB 3.24 billion in 2024, marking a 4.43% increase year-on-year. Net profits attributable to shareholders saw a substantial rise of 23.59%, reaching RMB 342 million. Projections for the first half of 2025 suggest an even more significant increase in net income, estimated between 70% and 100% year-on-year, driven by strong sales in key products like Coenzyme Q10 and Vitamin A, as well as domestic health products. This financial strength underpins its strategic initiatives, including a 1.5 times expansion of its Coenzyme Q10 production line, which was successfully tested in 2024, reinforcing its dominant global market share of approximately 50% as of March 2025.
Strategic Acquisitions and Market Penetration
In February 2024, the company, through its US subsidiary Doctor's Best Inc., initiated plans for a $17.2 million acquisition of another US-based nutritional supplements company. Simultaneously, there's a concerted effort to bolster e-commerce operations and establish a private ecological closed loop to enhance domestic market penetration.
Ownership Trends and Institutional Interest
Industry trends indicate a growing presence of institutional ownership, with various asset management firms acquiring stakes in the company. While no public announcements have been made regarding succession plans or potential privatization, the company's focus remains on resource integration and expanding its health industry chain, a key aspect of its Target Market of Xiamen Kingdomway Group.
Financial Performance Highlights
The company's financial health is robust, with 2024 operating revenues of RMB 3.24 billion and net profits of RMB 342 million. The first half of 2025 is projected to see net income increase by 70%-100% year-on-year, driven by strong product demand.
Market Position and Expansion
With an estimated 50% global market share in Coenzyme Q10 as of March 2025, the company is solidifying its leadership. The expansion of its Coenzyme Q10 production line in 2024 further supports this dominant position and future growth.
Xiamen Kingdomway Group Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Xiamen Kingdomway Group Company?
- What is Competitive Landscape of Xiamen Kingdomway Group Company?
- What is Growth Strategy and Future Prospects of Xiamen Kingdomway Group Company?
- How Does Xiamen Kingdomway Group Company Work?
- What is Sales and Marketing Strategy of Xiamen Kingdomway Group Company?
- What are Mission Vision & Core Values of Xiamen Kingdomway Group Company?
- What is Customer Demographics and Target Market of Xiamen Kingdomway Group Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.